ReviewAnnals of gastroenterology
Role of cannabis in inflammatory bowel diseases.
Review in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- CB2R promotes T cell gut homing and exacerbates ileitis in a murine Crohn's model.Inflammatory bowel diseases · 2026Article
- WIN55,212-2 attenuates intestinal fibrosis in a DSS-induced mouse model.Pharmacological reports : PR · 2026Article
- The Endocannabinoid System in Human Disease: Molecular Signaling, Receptor Pharmacology, and Therapeutic Innovation.International journal of molecular sciences · 2025Review
- Unraveling the Enigma of Cannabinoid Hyperemesis Syndrome: A Narrative Review of Diagnosis and Management.Cureus · 2025Review
- Uncovering mechanism of hepatotoxicity diseases caused by tetrahydrocannabinol based on novel network toxicology and experimental verification.Scientific reports · 2025Article
- A Comprehensive Review and Update on Cannabis Hyperemesis Syndrome.Pharmaceuticals (Basel, Switzerland) · 2024Review
- The Potential of Cannabis in Managing Inflammatory Bowel Disease and Its Future Perspective.Cureus · 2024Review
- Complementary medicines used in ulcerative colitis and unintended interactions with cytochrome P450-dependent drug-metabolizing enzymes.Turkish journal of medical sciences · 2022Review
- Electroacupuncture Reduces Visceral Pain Via Cannabinoid CB2 Receptors in a Mouse Model of Inflammatory Bowel Disease.Frontiers in pharmacology · 2022Article
- Chronic cannabis smoking-enriched oral pathobiont drives behavioral changes, macrophage infiltration, and increases β-amyloid protein production in the brain.EBioMedicine · 2021Article
- Cannabis and Its Potential Protective Role Against Inflammatory Bowel Disease: A Scoping Review.Cureus · 2021Article
- The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases.International journal of molecular sciences · 2021Review
- Inflammatory Bowel Disease and Cannabis: A Practical Approach for Clinicians.Advances in therapy · 2021Review
- Polarity scaffolds signaling in epithelial cell permeability.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Review
- Cannabis and Autoimmunity: Possible Mechanisms of Action.ImmunoTargets and therapy · 2021Review
- Article
- It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.Molecules (Basel, Switzerland) · 2020Review
- Self-reported cannabis use and biomarkers of inflammation among adults in the United States.Brain, behavior, & immunity - health · 2020Article
- Cannabis and Canabidinoids on the Inflammatory Bowel Diseases: Going Beyond Misuse.International journal of molecular sciences · 2020Review
- Cannabis hyperemesis syndrome: an update on the pathophysiology and management.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For many centuries, cannabis (marijuana) has been used for both recreational and medicinal purposes. Currently, there are about 192 million cannabis users worldwide, constituting approximately 3.9% of the global population. Cannabis comprises more than 70 aromatic hydrocarbon compounds known as cannabinoids. Endogenous circulating cannabinoids, or endocannabinoids, such as anandamide and 2-arachidonoyl-glycerol, their metabolizing enzymes (fatty acid amide hydrolase and monoacylglycerol lipase) and 2 G-protein coupled cannabinoid receptors, CB1 and CB2, together represent the endocannabinoid system and are present throughout the human body. In the gastrointestinal (GI) tract, the activated endocannabinoid system reduces gut motility, intestinal secretion and epithelial permeability, and induces inflammatory leukocyte recruitment and immune modulation through the cannabinoid receptors present in the enteric nervous and immune systems. Because of the effects of cannabinoids on the GI tract, attempts have been made to investigate their medicinal properties, particularly for GI disorders such as pancreatitis, hepatitis, and inflammatory bowel diseases (IBD). The effects of cannabis on IBD have been elucidated in several small observational and placebo-controlled studies, but with varied results. The small sample size and short follow-up duration in these studies make it difficult to show the clear benefits of cannabis in IBD. However, cannabis is now being considered as a potential drug for inflammatory GI conditions, particularly IBD, because of its spreading legalization in the United States and other countries and the growing trend in its use. More high-quality controlled studies are warranted to elucidate the mechanism and benefits of cannabis use as a possible option in IBD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.